Biotechs see sluggish sales for psoriasis drugs

01/24/2007 | NYTimes.com

Biotech firms are seeing flat sales for psoriasis drugs -- which can cost $10,000 to $35,000 a year -- because insurers are requiring patients to try older, less expensive treatments before they will reimburse the newer drugs, often to the dismay of physicians and patients. Amgen, Biogen Idec and Genentech developed psoriasis drugs and originally forecast they would be as successful as similarly expensive drugs for arthritis, cancer and multiple sclerosis.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ